Astigmatism Market

Market Overview:

The 7 major astigmatism markets reached a value of US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1.9 Billion by 2034, exhibiting a growth rate (CAGR) of 3.49% during 2024-2034.

The astigmatism market has been comprehensively analyzed in IMARC's new report titled "Astigmatism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Astigmatism refers to a common eye condition that affects the way light enters the eye, causing blurred or distorted vision. In this disease, the cornea (front surface of the eye) or the lens inside the eye has an irregular shape, due to which light rays focus on multiple points rather than a single point on the retina. Individuals suffering from the ailment may experience eye strain, fatigue, distorted or tilted vision, eye discomfort, headaches, squinting, trouble seeing at night, difficulty focusing, etc. The diagnosis of astigmatism is typically made through a detailed medical history assessment, a clinical feature evaluation, and an eye examination by an ophthalmologist. The healthcare provider will conduct refraction tests using a phoropter to measure the amount of refractive error in patients. Corneal topography may also be recommended to obtain a comprehensive map of the cornea's curvature that helps to detect any irregularities or abnormalities indicative of the illness. In some cases, additional workups, such as visual acuity tests, keratometry, retinoscopy, etc., are utilized to confirm a diagnosis and rule out other possible causes. 

The rising cases of trauma to the eye, such as a penetrating injury, which can alter the shape of the cornea or lens, are primarily driving the astigmatism market. Furthermore, the increasing prevalence of genetic predisposition that results in gene variations, thereby affecting the development of the cornea, lens, and other components of the eye, is also propelling the market growth. Besides this, the widespread adoption of orthokeratology, since it involves wearing specially designed gas-permeable contact lenses overnight to reshape the cornea and correct astigmatism, is acting as another significant growth-inducing factor. Additionally, the inflating usage of vision therapy, involving a series of exercises and techniques that aim to improve visual skills as well as reduce disease-related symptoms, is further bolstering the market growth. Apart from this, the escalating demand for laser-assisted in situ keratomileusis (LASIK) procedure, owing to its numerous advantages, such as correcting vision problems, providing relatively faster results, and enhancing the quality of life in patients, is expected to drive the astigmatism market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the astigmatism market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for astigmatism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the astigmatism market in any manner.

Recent Developments:

• In February 2024, Swiss Advanced Vision (SAV-IOL SA) announced the release of new features for its Toric Calculator, which improves the entire computation experience. For the first time, ophthalmologists will be able to use a web-based configurator to help define the ideal incision position to reduce residual astigmatism after surgery based on the patient's optical data.
• In January 2024, Bausch + Lomb Corporation stated that the U.S. Food and Drug Administration (FDA) had approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism.

Key Highlights:

• Astigmatism prevalence in the general population can range from 8-62%, with greater rates in those aged 70 and older.
• The most common type of astigmatism is mild astigmatism, accounting for approximately 82% of all reported astigmatisms.
• In Europe and Asia, astigmatism affects 30-60% of individuals.
• An American study found that nearly three in ten youngsters (28.4%) aged five to seventeen have astigmatism.
• Most people with myopia (nearsightedness) or hyperopia (farsightedness) have some degree of astigmatism.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the astigmatism market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the astigmatism market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current astigmatism marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance  

Key Questions Answered in this Report:

Market Insights

• How has the astigmatism market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the astigmatism market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the astigmatism market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of astigmatism across the seven major markets?
• What is the number of prevalent cases (2018-2034) of astigmatism by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of astigmatism by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with astigmatism across the seven major markets?
• What is the size of the astigmatism patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of astigmatism?
• What will be the growth rate of patients across the seven major markets?
   

Astigmatism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for astigmatism drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the astigmatism market?
• What are the key regulatory events related to the astigmatism market?
• What is the structure of clinical trial landscape by status related to the astigmatism market?
• What is the structure of clinical trial landscape by phase related to the astigmatism market?
• What is the structure of clinical trial landscape by route of administration related to the astigmatism market?